InvestorsHub Logo
Followers 72
Posts 6896
Boards Moderated 0
Alias Born 12/07/2011

Re: DaubersUP post# 214087

Thursday, 01/25/2018 6:28:18 AM

Thursday, January 25, 2018 6:28:18 AM

Post# of 403039
“Research by BIDMC combined Kevetrin™ with sunitinib on cell line 786, a drug-resistant renal cancer. Cellceutix was advised by the researchers that “the Kevetrin/sunitinib combination is the first we’ve used in which actual tumor shrinkage is noted.”
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News